[Pubmed] Robotic Extended Thymectomy in Late-Onset Myasthenia Gravis: A 21-Year Retrospective Cohort Study of 172 Patien
-
RSS-Bot
Auteur du sujet - Ami(e) de Diamant

- Messages : 6511
- Enregistré le : 31 mai 2020 09:57
- 6
- Zodiaque :
- Âge : 22
- Contact :
[Pubmed] Robotic Extended Thymectomy in Late-Onset Myasthenia Gravis: A 21-Year Retrospective Cohort Study of 172 Patien
Eur J Neurol. 2025 Nov;32(11):e70388. doi: 10.1111/ene.70388.
ABSTRACT
BACKGROUND: The safety and feasibility of robotic-assisted (RATS) thymectomy for myasthenia gravis (MG) with onset age ≥ 50 years remain unverified, particularly in very late-onset MG (V-LOMG).
METHODS: Patients were classified into late-onset MG (LOMG, 50-64) and very late-onset MG (V-LOMG ≥ 65) based on age of onset. Composite neurological remission (CNR) included complete stable remission (CSR), pharmacologic remission (PR), and minimal manifestations-0 (MM-0), while favorable outcomes comprised CNR and MM1-3.
RESULTS: Among 1041 patients, 172 with MG onset at ≥ 50 years who underwent RATS extended thymectomy were included in the final analysis. The LOMG group comprised 104 patients (45.2% male), while the V-LOMG group included 68 patients (60.3% male). V-LOMG patients had more preoperative MG crises, shorter onset-to-thymectomy intervals, heavier thymic specimens, and less hyperplasia. In ocular-onset MG, generalization was more frequent in LOMG than in V-LOMG. No significant differences were found in other baseline characteristics, perioperative parameters, postoperative complications, and adverse composite outcomes. At a 5.1-year mean follow-up, the V-LOMG group had slightly higher CSR (7.4% vs. 6.7%), CNR (16.2% vs. 11.5%), and favorable outcome rates (52.9% vs. 45.2%) than the LOMG group, with no statistical significance. Both groups, especially V-LOMG (16.0 mg vs. 2.1 mg, p < 0.001), showed a significant corticosteroid dose reduction at the last follow-up, confirming the steroid-sparing effect of thymectomy.
CONCLUSIONS: RATS extended thymectomy appears to be a safe and feasible treatment for patients with MG of onset at age ≥ 50 years, including those with V-LOMG, demonstrating a significant steroid-sparing effect while maintaining favorable neurological outcomes.
PMID:41190556 | PMC:PMC12587165 | DOI:10.1111/ene.70388
Source: https://pubmed.ncbi.nlm.nih.gov/4119055 ... 22+67771e2
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI
Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page

Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]
Bonne lecture...
Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page

Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]
Bonne lecture...





